Literature DB >> 10593707

Review of the Indian market of anti-tuberculosis drugs: focus on the utilisation of rifampicin-based products.

E Catalani1.   

Abstract

SETTING: There is a need to better understand the extent of the utilisation of rifampicin in the market, particularly in fixed-dose combinations (FDC).
OBJECTIVE: To review the Indian market of antituberculosis drugs, as this is the largest single market in the world of this therapeutic class.
DESIGN: Review and analysis of the sales data proffered by the Indian market audit. Estimated data relating to public sector product usage were utilised in order to obtain a more complete scenario.
RESULTS: The use of rifampicin-based products is very important in the Indian market of anti-tuberculosis drugs. Particularly common is the use of FDCs, which represent 62% of anti-tuberculosis drugs sold in the private market.
CONCLUSIONS: The Indian market for anti-tuberculosis drugs is very large and well integrated. FDCs are widely used. In addition to double- and triple-drug FDCs, four-drug combinations have recently been introduced into the market. The Indian industry also exports raw materials and pharmaceutical specialities.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10593707

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  2 in total

1.  What Can We Learn About the Processes of Regulation of Tuberculosis Medicines From the Experiences of Health Policy and System Actors in India, Tanzania, and Zambia?

Authors:  Kabir Sheikh; Mukund Uplekar
Journal:  Int J Health Policy Manag       Date:  2016-07-01

2.  The production and sales of anti-tuberculosis drugs in China.

Authors:  Yang-Mu Huang; Qi-Peng Zhao; Qiao-Meng Ren; Dan-Lu Peng; Yan Guo
Journal:  Infect Dis Poverty       Date:  2016-10-04       Impact factor: 4.520

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.